Q3 2020 Results

28 October 2020

Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2019 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our third quarter 2020 earnings release and Annual Report on Form 20-F for FY 2019.

All expectations and targets regarding future performance and the dividend should be read together with "Assumptions related to 2020 guidance and 2016-2020 outlook" on page 63 of our third quarter 2020 earnings release.

Agenda

Q3 2020 progress	Emma Walmsley, Chief Executive Officer	
Q3 2020 financial results	Iain Mackay, Chief Financial Officer	
Commercial execution	Luke Miels, President Global Pharmaceuticals David Redfern, Chief Strategy Officer, Chairman of ViiV	 
Consumer Healthcare	Brian McNamara, Chief Executive Officer, GSK Consumer Healthcare	
Summary	Emma Walmsley, Chief Executive Officer	

Q&A:
Hal Barron, Chief Scientific Officer, President R&D
Roger Connor, President, Global Vaccines

Emma Walmsley, CEO

28 October 2020

Q3 progress

Resilient performance, strong momentum on strategic priorities and COVID-19 response

Strengthened and advanced the pipeline

Competitive in-market execution

Disciplined cost control

Good progress on integration & separation

Progressed pandemic solutions

Innovation

- ✓ Blenrep US approval and launch in multiple myeloma; EC approval and first European launches
- ✓ Trelegy asthma US approval; Nucala progress on new indications*; Rukobia US approval and launch
- ✓ Positive data presented on RSV OA and maternal vaccines, GSK'836 in HBV; plans to advance development progressing
- ✓ Pivotal study starts in MenABCWY, Blenrep in 2L multiple myeloma, and Vir7831 in COVID-19

Performance

- ✓ Strong commercial execution driving new product growth
- ✓ Continued delivery of Consumer Healthcare JV integration
- ✓ Good progress on separation and transformation activities, and cost base optimisation

Trust

- ✓ Supply agreements in place with multiple governments for adjuvanted COVID-19 vaccine
- ✓ Industry pledge on COVID vaccine access and generation of safety data

* Nucala hypereosinophilic syndrome (HES) US approval, nasal polyposis (NP) US submission; EMA submissions for eosinophilic granulomatosis with polyangiitis (EGPA), NP and HES

Q3 performance

Pharma and Consumer growth drivers and cost control offset pandemic impacts

Pharmaceuticals
-3% CER

- New & Specialty Pharma +12%*
- Respiratory products +26%**
- HIV flat; 2DRs £222m, +94%
- Benlysta +13%; Oncology £99m, +58%

Vaccines
-9% CER

- Shingrix £374m, -25%
- Meningitis +1%
- Influenza +21%

Consumer Healthcare
+2% CER

- Pro forma -6%, (+3% excluding brands divested or under review)
- Gaining share overall and with power brands; VMS +18%, Oral Health +5%

Group sales -3%, pro forma -5%

30.8% Adjusted operating margin; +2.4 pp pro forma

Total EPS 25.0p, -9%; Adjusted EPS 35.6p, +1%

FCF £2.3 billion YTD

All growth rates and margin changes at CER. VMS: vitamins, minerals and supplements
The definitions for non-IFRS measures are set out on pages 10, 11 and 62 of our Third Quarter 2020 earnings release, and reconciliations are set out on pages 23 and 62.
* New & Specialty Pharma comprises Pharmaceuticals excluding Established Pharmaceuticals ** Respiratory comprises the Ellipta portfolio and Nucala

Progress on portfolio of COVID-19 solutions

3 vaccine approaches in the clinic

SANOFI

- Sanofi's recombinant protein-based antigen + GSK's AS03 adjuvant
- FTIH studies initiated September 2020
- Data expected by year end 2020; pivotal study start anticipated by year end

medicago

- Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) + GSK's AS03 adjuvant
- FTIH studies initiated July 2020
- Data expected to be published shortly; pivotal study start anticipated by year end

Clover Biopharmaceuticals

- Clover's COVID-19 S-Trimer vaccine (SCB 2019) + GSK's AS03 adjuvant
- FTIH studies initiated June 2020
- Data expected to be published shortly; pivotal study start anticipated by year end

2 therapeutics in pivotal studies

- **Vir7831**: neutralizing human monoclonal antibody, specifically engineered for SARS-CoV-2
- Potential to be best-in-class: designed for maximum bioavailability in the lung; long half-life following single infusion; optimal binding to virus even if it subsequently mutates
- COMET-ICE pivotal study ongoing with initial data possible by end 2020

- **otilimab**: aGM-CSF antibody, targeting a cytokine found in high levels in COVID patients
- For treatment of severe pulmonary COVID-19 related disease
- OSCAR study ongoing, with data expected 1H 2021
- Also in Phase 3 studies for rheumatoid arthritis

Q3 2020 financial results

Iain Mackay, CFO

Headline results

	Q3 2020	Reported %		Pro forma %	YTD 2020	Reported %		Pro forma %
	£m	AER	CER	CER	£m	AER	CER	CER
Turnover	**8,646**	(8)	(3)	(5)	**25,360**	2	4	(2)
Total operating profit	**1,858**	(13)	(2)	n/a	**6,722**	33	37	n/a
Total EPS	**25.0p**	(20)	(9)	n/a	**102.0p**	51	55	n/a
Adjusted operating profit	**2,665**	(4)	4	2	**7,089**	-	3	(3)
Adjusted EPS	**35.6p**	(8)	1	n/a	**92.6p**	(7)	(4)	n/a
Free cash flow	**(180)**	>(100)	n/a	n/a	**2,300**	(7)	n/a	n/a

Results reconciliation

Q3 2020

	Total results	Intangible amortisation	Intangible impairment	Major restructuring	Transaction related	Disposals, significant legal and other	Separation costs	**Adjusted results**
Turnover (£bn)	**8.6**							**8.6**
Operating profit (£bn)	**1.9**	0.2	0.1	0.3	0.4	(0.2)	<0.1	**2.7**
EPS (pence)	**25.0**	3.1	1.0	5.0	4.3	(3.2)	0.4	**35.6**
Q3 19 EPS (pence)	**31.4**	3.4	0.4	3.4	5.7	(5.7)	n/a	**38.6**

Pharmaceuticals

Q3 2020

Sales

All figures £m

Q3 2020 Total : £4,192m: -3% CER; -7% AER



Operating margin



Sales

- New launches: Trelegy, Nucala, Dovato, Juluca, Zejula
- Sustained Benlysta growth
- Impact of generics on Established products
- Pandemic-related lower demand for antibiotics

Operating profit

- Product mix
- Favourable 2019 one-offs comparison
- Tight control of costs
- Investment in new product support and targeted R&D

Vaccines

Q3 2020

Sales

All figures £m



Operating margin



Sales

- Pandemic environment impact
- Flu sales execution

Operating profit

- Operating leverage from pandemic-related sales decline
- Key brand investment

Consumer Healthcare

Q3 2020

Sales

All figures £m



Operating margin



Sales

- ⊕ VMS consumer usage
- ⊕ Sensodyne strength
- ⊕ Voltaren OTC switch in US
- ⊖ Reversal of Q2 stocking following systems cutover
- ⊖ Impact of divested brands

Operating profit

- ⊕ Synergy delivery and cost control
- ⊖ Impact of divested brands
- ⊖ Brand investment

Sales and Adjusted operating margins

Q3 2020

Sales

All figures £m



Adjusted operating margin



Adjusted operating profit to net income

Continued delivery of financial efficiency

	Q3 19 £m	Q3 20 £m
Operating profit	**2,786**	**2,665**
Net finance expense	(206)	(197)
Share of associates	17	11
Tax	(411)	(417)
Tax rate	15.8%	16.8%
Minorities	(275)	(287)
Net income	**1,911**	**1,775**

Free cash flow of £2.3bn



CCL: contingent consideration liability
RAR: Returns and rebates
* Net Capex includes purchases less disposals of PP&E and intangibles
** Net operating cash is net cash inflow from operating activities including changes in working capital, excluding restructuring, operating CCL, and significant legal payments
*** Other includes significant legal payments, net interest paid, income from associates and JVs and distributions to minorities

2020 guidance

Pharma & Consumer performance on track

Sustained recovery in adult vaccination rates

Delivering Integration & Restructuring programmes

Disciplined focus on cost management

FY 2020 guidance

Adjusted EPS

Down 1 to 4% CER

Tracking to lower end of range

All expectations and targets regarding future performance should be read together with the “Outlook assumptions and cautionary statement” sections of the Third Quarter 2020 Results Announcement and the cautionary statement slide included with this presentation

Commercial execution

Luke Miels
President Global Pharmaceuticals

David Redfern
Chief Strategy Officer, Chairman of ViiV

Nucala: market leadership with upside opportunity

Leading in eosinophilic indications

- £251m in Q3, +29% CER; remains the IL-5 market leader globally
- Growth opportunity:
  - 12-24m with SEA[1] globally but majority undertreated
  - ~420k patients in US; only 27% currently receive a biologic
- Rapid indication expansion:
  - Paediatric patients
  - First biologic with auto-injector for at home use
  - First biologic approved for EGPA[2] and HES[3]
  - First anti IL-5 with positive Ph3 data in NP[4]
  - Phase 3 study in COPD ongoing
  - Delivers proven efficacy by precisely targeting IL-5 to reduce eosinophils to normal levels

Global leader in IL-5 market share



1. Severe Eosinophilic Asthma 2. Eosinophilic granulomatosis with polyangiitis
3. Hypereosinophilic syndrome 4. Nasal Polyps

* Market share data sources: US (IQVIA DDD+ and Xponent data), Germany ("Sell Out Units ZE" from German PADDS-Pharmascope and "Zaehleinheit" from German PADDS-DKM dataset), France (IQVIA & GERS), Italy (IQVIA Volume Data), Spain (Atrys Health Severe Asthma - Biologic Market), Japan (IQVIA PEQ Data)

Trelegy: growing the market with leading performance

Strong performance with room to grow

- £194m in Q3, +45%
- Substantial COPD growth opportunity
  - <25% maintenance patients on triple therapy today
- Launched in 43 markets including China and Japan
- Further growth & differentiation opportunity in asthma
  - 5.8m US adult asthma patients on ICS/LABA – 30% uncontrolled
  - US approval received September 2020
  - Only once-daily triple approved for asthma in US; filed in EU and Japan

Market leading in US and other major markets

US triple therapy market share



Unmet need remains



Substantial room to grow the class with <27% of maintenance on a triple and only 42% of those on a triple taking Trelegy[3]

1 Lancet 2016 2. Source: IQVIA APLD; w/e Sep 18th, 2020
3. Treated with Maintenance: IQVIA Claims Data; Jan - Dec 2019; Patients on Triple Therapy and % Patients on Trelegy: Sourced from IQVIA Claims Data; Aug 2020

Benlysta: consistent growth in an expanding market

LCM driving sustained leadership in lupus

- £186m in Q3, +13% CER
- Life cycle management driving future growth
  - **Lupus Nephritis (LN):** US approval expected by year end
    - Positive data in NEJM[1]
    - FDA Breakthrough Designation & Priority Review
  - **Combination with rituximab**: BLISS-BELIEVE pivotal study ongoing
    - Primary endpoint data expected in-house end 2020
    - Possible filing 1H21
  - **China:** Successful launch of IV formulation; ~1m SLE[2] patients, expected to increase with increased diagnosis and treatment

Considerable unmet patient need remains



>80% of eligible US patients remain untreated with Benlysta, increasing with LN indication

1. Furie R, Rovin B, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Eng J Med. 2020;383:1117-112 2. SLE: Systemic Lupus Erythematosus

Source: Internal US estimates based on external epidemiology studies, claims data and market research
3. Benlysta eligible based on current labeling

Zejula: strong label and commercial execution drive share in 1LM OC

Best-in-class PARPi; opportunity for growth

- £92m in Q3, +47%; positive CHMP opinion for PRIMA
- 1st PARP inhibitor to show PFS[1] in first line ovarian cancer regardless of biomarker status
- Supportive guidelines from NCCN and ASCO
- Watch & wait approach still used in >70% of women in 1LM OC setting in the US[2]



- ZEAL-1L study in NSCLC to start shortly; demonstrated tumour penetration and ability to cross the blood brain barrier[3]

Increasing new patients starts in 1LM OC



46% of new 1LM patients getting a PARPi now receive Zejula[5]

31% of all PARPi patients (new and repeat) now on Zejula in 1LM[6]

1 PFS = Progression-free survival
2. Flatiron Health Jul 2020
3. Sun et al. Oncotarget 2018, Vol 9 (no 98)

4. Symphony Claims Data through August 2020 - Rolling 3 Week Average
5. Symphony Health Aug 2020
6. Flatiron Health Aug 2020

Blenrep: first-in-class treatment for multiple myeloma

Positive response, encouraging demand

- REMS fully operationalised; >500 HCPs enrolled
- 200+ patients enrolled in REMS (end Q3)
- Share of voice[1] amongst top 3 MM[2] treatments
- Included in NCCN Guidelines

- Highly-skilled and experienced salesforce
- In-person access to HCPs highest amongst MM competitive set[1]

Development in earlier lines continues

- Studying optimal dosing volume and scheduling
- Investigating synergistic combinations:
  - DREAMM-5 platform study; preliminary data on GSI combination expected 2021
  - DREAMM-4 combination with pembrolizumab; data in-house, presentation expected 1H21

Upcoming read-outs



1. Brand Impact Report; Sept 2020
2. Multiple Myeloma

Shingrix: encouraging recovery of demand trends

US vaccination rates at pre COVID levels

- £374m in Q3, -25% CER
- US TRx recovered to pre COVID and Q3 2019 levels by quarter end
  - DTC campaigns underway in conjunction with flu season
  - ~75% still completing second dose in series
- EU growth driven by robust demand in Germany
- Phased launch in China private pay market progressing well
- Capacity expansion progressing well

US demand trends recovering



* Volume estimate of doses administered, based on weekly IQVIA TRx data (~65% of doses administered) grossed up to 100%

Vir collaboration: potential best-in-class antibody for COVID-19

Differentiated antibody approach

- Vir-7831 potently **neutralises SARS-Cov-2**
- **High barrier of resistance**[1] due to unique binding properties and a highly conserved epitope
- **Highly potent allowing for a lower dose** and has the ability to recruit other immune cells to kill already infected cells[2,3]
- Has a "LS mutation"[5] which **extends the antibody half life** and increases the amount of the drug in the lung



COMET-ICE study ongoing in patients at high risk of hospitalisation; preliminary data expected by end 2020

Significant unmet need

- Clear need for therapeutics despite active vaccine development programmes
- Significant demand for COVID-19 mAbs
- Around 5% of infections are thought to require hospitalisation, based on data to date

Additional opportunities planned

- Phase 3 study in hospitalised patients with severe COVID-19
- Phase 3 study for prevention of symptomatic infection
- Vir-7832 Phase 2 study

1. Adapted from Pinto et al. Nature (published online May 18, 2020). https://doi.org/10.1038/s41586-020-2349-y
2. Piccoli et al, Cell (published online September 16, 2020). https://doi.org/10.1016/j.cell.2020.09.037
3. Schafer et al, BioRxib (published on line September 15, 2020). https://doi.org/10.1101/2020.09.15.298067
4. Vir Investor Presentation https://investors.vir.bio/static-files/a14f9b2a-d9aa-4793-aa41-b2eee1fb33e7
5. Ko et al. Nature 2014;514(7524):642-5

Strong momentum on 2DRs

Strong execution across portfolio

- Leading share of voice in US and Europe
- Strong execution with 2DRs, driving uptake (NBRx: >8%)
- Dovato US label expansion to include TANGO data; driving increased share in switch market
- Additional supportive data from 96-week TANGO switch and 144-week GEMINI studies
- Positive start for Rukobia; US insurance coverage 70%
- CAB PrEP filing with FDA on track for H1 2021 – approval anticipated Q1 2022

US DTG NBRx share outpacing DTG TRX share



Market at point of inflection as 2DRs gain traction

Consumer Healthcare

Brian McNamara,
CEO GSK Consumer Healthcare

Integration update

Successful to date and firmly on track

Key milestones

- 96% of PCH sales on our book with one system
- 71 systems cutovers in the last 7 months
- 87% of co-locations complete
- 39 out of 41 warehouses closed
- Future market cutovers, employee transfers, and local legal closes on track

Synergies

- £500m 2022 annual synergy target remains on track, with 40% total in 2020, c.80% in 2021 and full amount in 2022
- Continue to expect up to 25% to be reinvested
- Margin guidance maintained
- Separation program on track

Divestment

- Transactions signed to meet £1 billion proceeds target[1]
- Divested more than 50 growth dilutive brands
- Rationalisation and strengthening of existing portfolio

[1] As of date of Q3 2020 results

World class portfolio with category leading positions

Top 4 categories, additionally #1 positions in Digestive Health and Smoker's health[1]

Pain Relief	Respiratory	Therapeutic Oral Health	Vitamins, Minerals and Supplements
Voltaren The joy of movement	Theraflu	Sensodyne	Emergen-C
Excedrin	Otrivin	Polident	Caltrate
Advil	Robitussin	Dr. BEST	Benefiber
Panadol	Flonase Allergy Relief	parodontax	Centrum
芬必得 Fenbid			
Category position			
#1	#1	#1	#1

[1] All categories ex Therapeutic Oral Health based on Nicholas Hall© DB6 Consumer Healthcare Database FY2019, Therapeutic Oral Health is based on Nielsen and IRI data

Consumer Healthcare Ytd Performance

Revenue +6%[1], gaining share overall[2] , with strong ecommerce growth

Vitamins, Minerals and Supplements	▪ Beneficiary of continued consumer focus on health and wellness ▪ Strong performance from Centrum, Emergen-C and Caltrate ▪ On proforma basis sales continued to grow in high teens, and c.1.5x market
Digital Commerce	▪ Strong across all categories ▪ Now globally >6% sales[3] , higher share in key countries such as US and China ▪ Gaining share overall[3]
Power brands	▪ 5 of the 9 power brands up high single digit or double digit ▪ Collectively the power brands gained share, with 8 of the 9 gaining or holding share
Innovation	▪ Sensodyne Sensitivity and Gum launched in 11 markets ▪ Successful Voltaren Rx-to-OTC switch in the US market ▪ Launch of Advil Dual action at the end of Q3 in the US
Market volatility	▪ Some additional unwind of accelerated purchases in Q3 from Q1, particularly in respiratory ▪ Early in cold and flu season but significantly lower incidence levels seen to date, too early to predict

[1] CER Proforma excluding brands divested / under review

[2] All analysis and market share data GSK analysis based on Nielsen, IQVIA and IRI data

[3] Based on August YTD data

Maintaining momentum; delivering long term priorities

While bringing solutions to COVID-19

2020 focus

Innovation

Performance

Trust

- ✓ – Progress pipeline
- ✓ – Drive operating performance
- ✓ – Successful integration
- ✓ – Prepare for 2 new companies

New GSK: a leading biopharma company with R&D focused on science of the immune system, genetics and advanced technologies

New leading Consumer Healthcare company with category leading power brands and science and consumer insights

Appendix

Sales and Adjusted operating margins

Q3 YTD 2020

Sales

All figures £m



Adjusted operating margin



Innovation

Our R&D pipeline

40 medicines and 18 vaccines

First time in human (Phase 1)

- **3858279* (CCL17 inhibitor)** OA pain
- **3745417 (STING agonist)** cancer
- **3186899* (CRK-12 inhibitor)** visceral leishmaniasis
- **3511294* (LA anti-IL5 antagonist)** asthma
- **3810109* (broadly neutralizing antibody)** HIV
- **3537142* (NYESO1 ImmTAC)** cancer
- **3439171* (H-PGDS inhibitor)** DMD
- **3368715* (Type 1 PRMT inhibitor)** cancer
- **3174998* (OX40 agonist)** cancer
- **2798745* (TRPV4)** DME
- **6097608* (CD96)** cancer
- **2982772 (RIP1-k)** psoriasis
- **3882347* (FimH antagonist)** uUTI
- **3739937 (maturation inhibitor)** HIV
- **3923868 (PI4kβ inhibitor)** viral COPD exacerbations
- **3901961* (CD8 TCR)** cancer
- **3845097* (TGFbR2 TCR)** cancer
- **3494245* (proteasome inh)** visceral leishmaniasis
- **C. difficile***
- **SAM (rabies model)**
- **S. aureus***
- **COVID-19 (Clover Biopharmaceuticals)*ł**
- **COVID-19 (Medicago)*ł**
- **COVID-19 (Sanofi)*ł2**

Proof of concept (Phase 1b/2)

- **3640254 (maturation inhibitor)** HIV
- **3228836* (HBV ASO)** HBV
- **2330811 (OSM antagonist)** systemic sclerosis
- **linerixibat (IBATi)** cholestatic pruritus in PBC
- **3326595* (PRMT5 inhibitor)** cancer
- **cobolimab* (TSR-022, TIM-3 antagonist)** cancer
- **3036656* (leucyl t-RNA inhibitor)** TB
- **2831781* (aLAG3 depleting)** ulcerative colitis
- **4074386* (TSR-033, LAG3 antagonist)** cancer
- **Menveo liquid**
- **RSV paediatric**
- **RSV maternal***
- **RSV older adults*2**
- **Therapeutic HBV*2**
- **Malaria* (fractional dose)**
- **Shigella***

Pivotal (Phase 2/3)

- **Benlysta3 + Rituxan** SLE**
- **cabotegravir** LA + rilpivirine* LA** HIV
- **daprodustat (HIF-PHI)** anemia
- **Nucala** COPD / nasal polyps
- **Blenrep* (BCMA ADC)** multiple myeloma
- **Zejula* (PARP inhibitor)** ovarian cancer**
- **dostarlimab* (PD-1 antagonist)** dMMR/MSI-H EC
- **bintrafusp alfa* (TGFβ trap/anti-PDL1)** BTC**
- **otilimab* (3196165, aGM-CSF inhibitor)** RA**4
- **gepotidacin* (2140944)** uUTI and GC
- **3359609* (ICOS receptor agonist)** HNSCC**1
- **letetresgene-autoleucel* (3377794, NY-ESO-1 TCR)** SS**
- **4182136* (Vir-7831)** COVID-19
- **Shingrix immuno-compromised***
- **Bexsero infants (US)**
- **MMR (US)**
- **Rotarix liquid (US)**
- **MenABCWY**

Rx **Vx**

Note: Only the most advanced indications are shown for each asset

*In-license or other alliance relationship with third party
**Additional indications also under investigation
ł GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
1. ICOS HNSCC is a Phase 2/3 study with registrational potential
2. In Phase 1/2 study
3. Benlysta for lupus nephritis in registration
4. Otilimab for COVID-19 therapy in Ph2

RA: rheumatoid arthritis; OA: osteoarthritis; DMD: duchenne muscular dystrophy; PBC: primary biliary cholangitis; TB: tuberculosis; SLE: systemic lupus erythematosus; BTC: biliary tract cancer; EC: endometrial cancer; uUTI: uncomplicated urinary tract infection; GC: gonorrhoea; HNSCC: head and neck squamous cell carcinoma; dMMR: deficient mismatch repair; DME: diabetic macular edema

Innovation

Upcoming milestones that will inform our progress

	2H 2020	1H 2021	2H 2021	1H 2022	2H 2022
Anticipated submission	Nucala NP	✓ Benlysta + Rituxan SLE	bintrafusp alfa (TGFβ trap/anti-PDL1) BTC	Dostarlimab (PD-1) combo with CT 1L EC (RUBY)	belantamab mafodotin (BCMA) 3L in MM (DREAMM-3)
	Shingrix IC (US)	✓ dostarlimab (PD-1) dMMR pan-tumor	Zejula + dostarlimab 2L+ PROC (MOONSTONE)[4]	daprodustat (HIF-PHI) anemia	
		cabotegravir HIV PrEP			
		4182136 (Vir-7831) COVID-19			
		MMR (US)			
Pivotal data	Benlysta + Rituxan SLE[1]	bintrafusp alfa BTC	dostarlimab combo with CT 1L EC (RUBY)	belantamab mafodotin (BCMA) 3L in MM (DREAMM-3)	belantamab mafodotin (BCMA) + Pd 2L+ in MM (DREAMM-8)
	dostarlimab (PD-1) dMMR pan-tumor	✓ 4182136 (Vir) COVID-19[3]	Zejula + dostarlimab 2L+ PROC (MOONSTONE)[4]	gepotidacin uUTI[5]	MenABCWY
			daprodustat anemia		RSV older adults[6]
					RSV maternal[6]
PoC data	2330672 (linerixibat, IBAT inhibitor) cholestatic pruritus in PBC[2]	3359609 (ICOS) ENTRÉE lung platform - docetaxel	cobolimab (TIM-3) NSCLC (AMBER)	belantamab mafodotin (BCMA) 1L combo in MM (DREAMM-9)	
	belantamab mafodotin (BCMA) PD-1 combo in MM (DREAMM-4)	✓ 2831781 (aLAG3 depleting) UC*	3036656 (leucyl t-RNA) tuberculosis*	3228836 (HBV-ASO) HBV[2]	
	COVID-19 (Clover Biopharmaceuticals)	otilimab (aGM-CSF) COVID-19	lete-cel (3377794 NY-ESO) NSCLC* therapy		
	COVID-19 (Medicago)		S. Aureus interim data*		
	COVID-19 (Sanofi)				

Key:

- ✓ +ve data in-house, decided to progress
- ✓ +ve data in-house, decision pending
- ⇔ data in-house, additional data needed
- -ve data in-house, return to research
- ✘ -ve data in-house, decided to terminate

MM: multiple myeloma; NP: nasal polyposis; PrEP: pre-exposure prophylaxis; SLE: systemic lupus erythematosus; UC: ulcerative colitis; NSCLC: non-small cell lung cancer; PBC: primary biliary cholangitis; EC: endometrial cancer; PROC: Platinum resistant ovarian cancer; BTC: biliary tract cancer; dMMR: deficient mismatch repair

*Interim Analysis (internal) 1. Primary data in-house at 52 weeks, study completion at 104 weeks 2. Phase 2b study 3. Also delivers PoC data 4. Study temporarily held recruitment activities to perform a pre-planned interim analysis 5. interim analysis subject to regulators feedback 6. Initial data, timing dependent on RSV infection circulation during pandemic lockdowns

Note: tick marks refer to programmes on left side of marks

Innovation

Changes in portfolio since Q2 2020

Changes to pipeline

New to Phase I	New to Phase I expansion/ Phase II	New to Pivotal	New to Registration
GSK3882347 (FimH antagonist) uUTI **GSK3739937 (maturation inhibitor)** HIV **GSK3901961 (CD8 TCR)** cancer **GSK3845097 (TGFbR2 TCR)** cancer **GSK2982772 (RIP1-k)** psoriasis* **GSK3923868 (PI4kβ inhibitor)** viral COPD exacerbations **COVID-19 (Sanofi)** ǂ **3494245* (proteasome inh)** visceral leishmaniasis		**GSK3377794** letetresgene-autoleucel (NY-ESO-1 TCR) synovial sarcoma **GSK4182136 / Vir-7831** COVID-19 **MenABCWY vaccine**	**mepolizumab (NP)**

*Ph1b study in psoriasis
ǂ GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations

Removed from Phase I	Removed from Phase I expansion/ Phase II	Removed from Pivotal	Removed from Registration
	GSK3772847 (IL-33r antagonist) asthma		**Trelegy (asthma)** FDA approval **mepolizumab (HES)** FDA approval

Changes to milestones

gepotidacin (GSK2140944) uUTI: **pivotal study interim analysis for uUTI indication moved from 2H 2021 to 1H2022 due to study design changes and impact of COVID-19**

daprodustat (HIF-PHI) anemia: **pivotal data expected 2H 2021, with submission 1H 2022**

letetresgene-autoleucel (NY-ESO-1 TCR) NSCLC: **PoC readout moved from 1H 2021 to 2H 2021 due to impact of COVID-19**